George Church’s GRObio Secures $60 Million to Advance Gout Treatment into Clinical Trials

1. Funding: GRObio has secured $60.3 million in Series B funding to advance its gout treatment, ProGly-Uricase, into human clinical trials.
2. Background: GRObio was spun out of George Church's Harvard Medical School lab in 2021 with initial Series A funding of $25 million.
3. Treatment Focus: ProGly-Uricase targets severe, refractory gout, aiming to improve treatment options for patients.
4. Clinical Entry: The fresh funding will enable GRObio to enter the clinic with its treatment, marking a significant milestone for the biotech company.
5. Competitive Landscape: GRObio aims to compete with established players like Amgen in the gout treatment market.